Article
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
BMC cancer - 1 Jun 2022
Nokihara Hiroshi, Ogino Hirokazu, Mitsuhashi Atsushi, Kondo Kensuke, Ogawa Ei, Ozaki Ryohiko, Yabuki Yohei, Yoneda Hiroto, Otsuka Kenji, Nishioka Yasuhiko
Abstract excerpt
BACKGROUND: Osimertinib is a standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Although malignant pleural effusion (PE) is a common clinical problem in NSCLC, information about the efficacy of osimertinib in patients with PE is limited, especially regarding its efficacy in EGFR T790M-negative patients with PE remains unclear....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.